Hemab Therapeutics doses first participant in Phase 1 trial of heavy menstrual bleeding drug HMB-003

• Hemab Therapeutics started a Phase 1 trial of HMB-003 for heavy menstrual bleeding, dosing the first healthy volunteer.
• No clinical results have been presented; initial Phase 1 readouts are expected to guide development plans by mid-2027.
• Program targets a long-acting, non-hormonal option intended to reduce heavy bleeding with less frequent dosing than current therapies.
• Study will assess safety and drug behavior in the body to support dose selection for later-stage trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609170800PRIMZONEFULLFEED9828476) on September 17, 2026, and is solely responsible for the information contained therein.